21.87  2.57 (13.32%)		03-31 16:00
Open: 20.37 High: 22.22 Volume: 2,998,472		Pre. Close: 19.3 Low: 20.37 Market Cap: 1,922(M)

Short term
Mid term
Targets	6-month :	26.79	1-year :	31.29
Resists	First :	22.94	Second :	26.79
Pivot price	20.51
Supports	First :	20.6	Second :	19.15
MAs	MA(5) :	20.29	MA(20) :	20.77
	MA(100) :	21.04	MA(250) :	14.47
MACD	MACD :	-0.5	Signal :	-0.6
%K %D	K(14,3) :	34.4	D(3) :	22.2
RSI	RSI(14): 54.9
52-week	High :	27.64	Low :	5.15

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ IMNM ] has closed Bollinger Bands are 40.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	19.9 - 20.03	20.03 - 20.14
Low:	18.91 - 19.04	19.04 - 19.14
Close:	19.11 - 19.32	19.32 - 19.49

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Tue, 31 Mar 2026
Insider Buying: Clay Siegall Acquires Shares of Immunome Inc (IM - GuruFocus

Tue, 31 Mar 2026
Immunome CEO Clay Siegall buys $500k in shares By Investing.com - Investing.com South Africa

Tue, 31 Mar 2026
Immunome CEO Clay Siegall buys $500k in shares By Investing.com - Investing.com India

Tue, 31 Mar 2026
Immunome (IMNM) CEO adds 25,450 shares in $19.67 stock purchase - Stock Titan

Thu, 26 Mar 2026
Vanguard disaggregates holdings; IMNM shows 0 shares after realignment (IMNM) - Stock Titan

Thu, 26 Mar 2026
Don't Ignore The Insider Selling In Immunome - simplywall.st

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	113 (M)
Held by Insiders	9.432e+007 (%)
Held by Institutions	7.5 (%)
Shares Short	16,040 (K)
Shares Short P.Month	0 (K)

EPS	-2.1165e+008
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-3 %
Return on Assets (ttm)	84.7 %
Return on Equity (ttm)	-29 %
Qtrly Rev. Growth	6.94e+006 %
Gross Profit (p.s.)	-45.67
Sales Per Share	-23.79
EBITDA (p.s.)	-7.77808e+007
Qtrly Earnings Growth	-2.5 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-191 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.92
Price to Cash Flow	8.53

Dividend	0
Forward Dividend	1.789e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.